{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-054856","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.264735+00:00","generated_at":"2026-05-20T04:12:41.356474+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"ReShape Lifesciences receives Nasdaq delisting notice; intends to appeal","bullets":["Nasdaq determined to delist RSLS for failing to meet $2.5M stockholders' equity requirement by May 27, 2025 extension deadline.","Trading will be suspended June 6 unless the company appeals by June 4; a Form 25-NSE will then remove securities from listing.","Company intends to appeal to a Nasdaq hearings panel, which would stay suspension pending decision.","No assurance hearings panel will grant continued listing or that compliance with listing rules can be maintained."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-054856","json":"https://secwatch.observer/filing/0001104659-25-054856.json","markdown":"https://secwatch.observer/filing/0001104659-25-054856.md","text":"https://secwatch.observer/filing/0001104659-25-054856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000110465925054856/0001104659-25-054856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000110465925054856/tm2516583d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:12:41.356474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62396f1b5755e6b49fb91e53bc3d2a9d924baaea","claim":"Vyome Holdings, Inc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"May 28, 2025, ReShape Lifesciences Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that Nasdaq has determined to delist the Company’s securities from Nasdaq. On November 25, 2024, Nasdaq notified the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b). However, Nasdaq granted the Company’s request for an extension until May 27, 2025 to comply with this requirement. Nasdaq has determined that","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465925054856/0001104659-25-054856-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}